2 completed, 1 active not recruiting, 1 recruiting, 1 withdrawn. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
Follow ROS1 Gene Mutation: new trials by email Literature Review of ROS1 Gene Mutation trials Research Report on ROS1 Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation Osimertinib, Alectinib 150 MG, Crizotinib 250 MG - Non Small Cell Lung Cancer, EGFR Gene Mutation | Phase 2 | Recruiting | Hunan Province Tumor Hospital | 6000 | 2020-04-16 | 2024-10-22 |
| Genetic Testing in Guiding Treatment for Patients With Brain Metastases Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib - CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain | Phase 2 | Active not recruiting | Alliance for Clinical Trials in Oncology | 50 | 2019-10-17 | 2026-10-30 |
| A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab, Carboplatin + Pemetrexed + Atezolizumab - NSCLC Stage IIIB, NSCLC Stage IV | Phase 2 | Completed | Centre Francois Baclesse | 150 | 2019-09-26 | 2026-05-12 |
| Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers Brigatinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment - Advanced Malignant Neoplasm, ALK Fusion Protein Expression | Phase 2 | Withdrawn | Sameek Roychowdhury | 2019-03-20 | 2022-02-18 | |
| Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Laboratory Biomarker Analysis, Pembrolizumab, Recombinant EphB4-HSA Fusion Protein - ALK Gene Mutation, BRAF Gene Mutation | Phase 2 | Completed | University of Southern California | 42 | 2017-03-10 | 2025-10-22 |
Carcinoma, Non-Small-Cell Lung (3) · Brain Neoplasms (2) · Neoplasm Metastasis (2) · Squamous Cell Carcinoma of Head and Neck (1)
Neoplasms (5) · Neoplasms by Site (5) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Lung Diseases (3) · Lung Neoplasms (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3) · Brain Diseases (2) · Central Nervous System Diseases (2) · Central Nervous System Neoplasms (2) · Neoplastic Processes (2) · Nervous System Diseases (2) · Nervous System Neoplasms (2)
Pemetrexed (2) · brigatinib (2) · entrectinib (2) · 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine (1) · Bevacizumab (1) · Carboplatin (1) · Cisplatin (1) · Crizotinib (1) · Drug Therapy (1) · Erlotinib Hydrochloride (1) · Gefitinib (1) · abemaciclib (1) · adagrasib (1) · aflutinib (1) · alectinib (1)
Alliance for Clinical Trials in Oncology (1) · Centre Francois Baclesse (1) · Hunan Province Tumor Hospital (1) · Sameek Roychowdhury (1) · University of Southern California (1)
United States (3) · China (1) · France (1)
Jorge Nieva, MD (1) · Priscilla Brastianos, MD (1) · Sameek Roychowdhury, MD (1) · Yongchang Zhang, MD (1)
PMID 32479604, PMID 36801605, PMID 38830303
P30CA014089 (1), P30CA016058 (1), U10CA180821 (1)